Compare Crispr Therapeutics AG (CRSP) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Otis Worldwide Corp — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while Otis Worldwide Corp trades at $65.98 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 5.2× Crispr Therapeutics AG's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Otis Worldwide Corp for 66 Days on average.
| CRSP | OTIS | |
|---|---|---|
Market Cap | $4.88B | $25.17B |
Volume | 2,861,747 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $74.92 | $93.62 |
52-Week Low | $44.34 | $64.05 |
Typical Hold Time | 77 Days | 66 Days |
Enterprise Value | $3.30B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Otis Worldwide trades at $65.95, showing modest daily gains of 0.32% but remains near its 52-week low. The stock faces technical bearish signals with mixed fundamental performance - revenue growth remains stable at $14.43B (2025) but recent quarters show earnings misses. Analyst consensus is divided with 7 buy, 7 hold, and 1 sell ratings, while the company navigates margin pressures and China market challenges.
The outlook balances Otis's dominant market position and service-driven cash flows against margin pressures and weak equipment demand. With a $87 consensus price target suggesting 32% upside, the stock offers value but requires monitoring of service margin recovery and China exposure. Key risks include persistent cost inflation and execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
